We show that 244-MPT is a novel EGFR inhibitor with a distinct chemical structure from other TKIs (Figure 1A), and it markedly inhibited anchorage-independent growth of both gefitinib-sensitive and –resistant NSCLC cell lines (Figure 1C, 1E). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.